• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Candid Therapeutics

Can UCB’s $2.2bn Candid Therapeutics deal reset the future of autoimmune therapy?

By Pallavi Madhiraju on May 4, 2026   Pharma & Biotech  

Can UCB’s $2.2bn Candid Therapeutics deal reset the future of autoimmune therapy?

UCB is paying heavily for early autoimmune science. Candid tests whether T-cell engagers can move beyond oncology into immune reset.

Recent Posts

  • Why Ardent Health’s Bank of America fireside chat could matter for hospital sector sentiment
  • Can Siegfried turn Noramco’s controlled-substance expertise into a global CDMO edge?
  • Why Sequenex’s MedTech Innovator partnership matters for connected device startups
  • Could Cairn Surgical’s breast cancer locator cut repeat surgeries where wires fall short?
  • Purdue Pharma is gone. Can Knoa Pharma turn opioid profits into public health repair?
  • What Trividia Health’s TRUE METRIX correction reveals about diabetes device risk communication
  • Is volixibat the next major growth lever for Mirum Pharmaceuticals beyond LIVMARLI?
  • Can UCB’s $2.2bn Candid Therapeutics deal reset the future of autoimmune therapy?
  • Can adhesion and lower estrogen dosing make Viatris’s contraceptive patch stand out?
  • Telix just moved a brain cancer imaging asset into Europe’s regulatory fast lane
  • Could Kodiak’s KSI-101 become the first real biologic challenger in inflammatory eye disease?
  • Can Vector Science’s microneedle catheter patent crack one of oncology’s hardest delivery problems?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes